TECH · CIK 0000842023
What Bio-Techne Corporation told the SEC could break it.
Bio-Techne's disclosures cluster on its global footprint and the policy forces around it. About 44% of fiscal 2025 revenue came from outside the U.S. and it manufactures in Canada, Switzerland, China and the UK, leaving it exposed to FX, foreign IP and U.S.–China trade risk — and it flags that significant, rising U.S.–China tariffs are increasing the cost of the supplies and components it imports and may force surcharges or price increases. Its demand is also policy-sensitive, tied to customers' R&D spending and the availability of government research funding such as NIH, while on the supply side certain specialized or regulatory-qualified components come from a single or limited number of suppliers.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- US-China tariffs on imported supplies and componentsmedium
Significant tariffs between the U.S. and China remain in effect and have increased, and will continue to increase, Bio-Techne's cost of imported supplies and components and its cost to serve certain markets, potentially requiring surcharges or price increases.
“As of the date of this report, a number of the recently-imposed tariffs remain in effect, including significant tariffs between the U.S. and China. Collectively, these tariffs have increased and will continue to increase the cost to us of supplies and components we import, as well as our cost to serve certain markets, which in turn will require us to bear significant increased costs to do business, and/or implement surcharges, and/or increase the price of certain of our products.”
- government research funding & drug-pricing policy (customer demand)medium
Bio-Techne's demand depends on customers' R&D spending and the availability of government research funding (e.g. NIH), and on healthcare/drug-pricing policy; reductions could fluctuate or depress demand for its reagents and instruments.
“Research and development spending by our customers and the availability of government research funding can fluctuate due to changes in available resources, mergers of pharmaceutical and biotechnology companies, spending priorities, general economic conditions and institutional and governmental budgetary policies.”
SEC filing →As of 2025
Geographic concentration
- 44% international revenue; manufacturing in Canada/Switzerland/China/UKmedium
About 44% of Bio-Techne's fiscal 2025 revenue came from outside the U.S., with manufacturing operations in Canada, Switzerland, China and the UK, exposing it to foreign IP, FX, political and US-China trade risk.
“We operate globally, with manufacturing operations in Canada, Switzerland, China and the UK, and approximately 44% of our revenue in fiscal 2025 was from outside the United States.”
Sole-source dependency
- single/limited-source qualified componentsmedium
For certain components requiring particular specifications or regulatory qualifications, Bio-Techne relies on a single supplier or a limited number of suppliers; such sole/limited-source reliance can cause production interruptions, delays and inefficiencies.
“No single supplier is material, although for some components that require particular specifications or regulatory or other qualifications there may be a single supplier or a limited number of suppliers that can readily provide such components.”
SEC filing →As of 2025
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“We sell our products directly to customers who are primarily located in North America, Europe and China, as well as through a distribution agreement with Thermo Fisher Scientific.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch